Dibutyltin oxide → 5-{1-tert-Butyl-2-[5-(2H-tetrazol-5-yl)-2-[1,2,4]triazol-1-yl-phenyl]-1H-benzoimidazol-5-yl}-pyrimidin-2-ylamine
反応式
[NH2:1][C:2]1[N:7]=[CH:6][C:5]([C:8]2[CH:33]=[CH:32][C:11]3[N:12]([C:28]([CH3:31])([CH3:30])[CH3:29])[C:13]([C:15]4[CH:16]=[C:17]([CH:20]=[CH:21][C:22]=4[N:23]4[CH:27]=[N:26][CH:25]=[N:24]4)[C:18]#[N:19])=[N:14][C:10]=3[CH:9]=2)=[CH:4][N:3]=1.[N:34]([Si](C)(C)C)=[N+:35]=[N-:36].C([Sn](=O)CCCC)CCC>CN(C=O)C>[C:28]([N:12]1[C:11]2[CH:32]=[CH:33][C:8]([C:5]3[CH:6]=[N:7][C:2]([NH2:1])=[N:3][CH:4]=3)=[CH:9][C:10]=2[N:14]=[C:13]1[C:15]1[CH:16]=[C:17]([C:18]2[N:34]=[N:35][NH:36][N:19]=2)[CH:20]=[CH:21][C:22]=1[N:23]1[CH:27]=[N:26][CH:25]=[N:24]1)([CH3:29])([CH3:30])[CH3:31]参加物
5
反応物 3
生成物 1
試薬・触媒・溶媒 1
反応条件
- 温度
- 100 °C
実験手順
To a solution of 3-[5-(2-Amino-pyrimidin-5-yl)-1-tert-butyl-1H-benzimidazol-2-yl]-4-1,2,4-triazol-1-yl-benzonitrile (example 7) (100 mg, 0.23 mmol) in DMF (5 mL) are added azidotrimethylsilane (0.06 mL, 0.46 mmol) and dibutyltin oxide (175 mg, 0.69 mmol) at room temperature. The solution is heated up to 100° C. for 5 hours in a microwave reactor. The solution is cooled down and is extracted with Sat. NH4Cl (10 mL) and EtOAc (3×10 mL). The combined organic layer is dried with MgSO4 (500 mg) and is filtered. The filtrate is concentrated and the residue is purified by preparative HPLC to afford the title compound (10 mg, 9%) LCMS (ESMS): m/z: 479.40 (M++1).
後処理
- temperatureThe solution is cooled down
- extractionis extracted with Sat. NH4Cl (10 mL) and EtOAc (3×10 mL)
- dry with materialThe combined organic layer is dried with MgSO4 (500 mg)
- filtrationis filtered
- concentrationThe filtrate is concentrated
- customthe residue is purified by preparative HPLC
出典と根拠
- ORDレコード
- ord-ff8f22cc47954896ab5f66f463e7631e
- 出典データセット
- uspto-grants-2013_04
- 特許番号
- US08420655B2
反応ノート
読み込み中…